title: Safety of Abciximab injection during endovascular treatment of ruptured aneurysms.
abstract: OBJECTIVE
  We aimed to determine the safety of intra-arterial Abciximab injection in the management of thromboembolic complications during endovascular treatment of ruptured cerebral aneurysms.
  
  
  METHODS
  In a monocentric consecutive series of endovascular treatment of 783 ruptured aneurysms, 42 (5.3%) patients received Abciximab after the aneurysm was secured. Bleeding complications were registered and dichotomized as follows: new intracranial hemorrhage and peripheral bleeding. For each patient, World Federation of Neurosurgery (WFNS) subarachnoid hemorrhage (SAH) grade, shunting, and clinical outcomes in the post-operative period and at 3-6 months were recorded.
  
  
  RESULTS
  SAH WFNS grades were as follows: grade I n = 14, grade II n = 10, grade III n = 11, grade IV n = 4, grade V n = 3. Ten patients had intracranial hematoma additionally to the SAH prior to embolization. Four patients (9.5%) presented more blood on the post-embolization CT but only one suffered a new clinically relevant intracranial hemorrhage. Two patients (4.8%) experienced significant peripheral bleeding but none were associated with long-term disabilities. Fourteen patients had a shunt installed less than 24 h prior to Abciximab injection and one less than 48 h later. At 3-6-month follow-up, 31 patients (74%) achieved a modified Rankin Scale score (mRS) of 2 or less, six patients (14%) had a mRS of 3-5, three were dead (7%), and two were lost at follow-up.
  
  
  CONCLUSIONS
  When the aneurysm is secured, intra-arterial Abciximab injection is a low complication rate treatment modality for thromboembolic events during embolization of cerebral ruptured aneurysm.
authors.affiliation: CHUM Montréal, Neuroradiology, Montréal, Québec, Canada.
authors.forename: Jean-Christophe
authors.initials: JC
authors.lastname: Gentric
authors.affiliation: CHUM Montréal, Neuroradiology, Montréal, Québec, Canada.
authors.forename: Joelle
authors.initials: J
authors.lastname: Brisson
authors.affiliation: CHUM Montréal, Neuroradiology, Montréal, Québec, Canada.
authors.forename: André Lima
authors.initials: AL
authors.lastname: Batista
authors.affiliation: CHUM Montréal, Neuroradiology, Montréal, Québec, Canada.
authors.forename: Jimmy
authors.initials: J
authors.lastname: Ghostine
authors.affiliation: CHUM Montréal, Neuroradiology, Montréal, Québec, Canada.
authors.forename: Jean
authors.initials: J
authors.lastname: Raymond
authors.affiliation: CHUM Montréal, Neuroradiology, Montréal, Québec, Canada.
authors.forename: Daniel
authors.initials: D
authors.lastname: Roy
authors.affiliation: CHUM Montréal, Neuroradiology, Montréal, Québec, Canada alain.weill.chum@ssss.gouv.qc.ca.
authors.forename: Alain
authors.initials: A
authors.lastname: Weill
mesh_terms: D000077284:Abciximab; D000328:Adult; D000368:Aged; D017542:Aneurysm, Ruptured / Q000000981:diagnostic imaging / Q000628:therapy*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D002533:Cerebral Angiography; D004621:Embolization, Therapeutic / Q000379:methods*; D057510:Endovascular Procedures / Q000379:methods*; D005260:Female; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000008:administration & dosage*; D007269:Injections, Intra-Arterial; D002532:Intracranial Aneurysm / Q000000981:diagnostic imaging / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage*; D013923:Thromboembolism / Q000000981:diagnostic imaging / Q000517:prevention & control*; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D010975:Platelet Aggregation Inhibitors; D000077284:Abciximab
keywords: Abciximab; Safety; aneurysm coiling; cerebral aneurysm; subarachnoid hemorrhage